Preclinically, HER3-DXd exhibited durable responses and favorable toxicity profiles in lung, colorectal, breast, gastric, and melanoma cell line xenografts and PDX models (3–10 mg/kg) with negligible activity in HER3-low models [117,120,121]. The gene discussed is ERBB3; the disease is melanoma.